The appropriate treatment for patients with coexistent chronic obstructive pulmonary disease (COPD) and heart failure (HF) remains unclear. Data from the Taiwan National Health Insurance Research Database was used for this retrospective cohort study. Patients diagnosed with both diseases between 1997 and 2012 were enrolled as the COPD-heart failure overlap cohort. Patients were categorized as non-users and users of specific COPD and HF medications. Medication prescriptions in each 3-month and 1-year period served as time-dependent covariates. The primary endpoint was cumulative survival. The validation study confirmed the accuracy of definitions of COPD (94.0% sensitivity) and HF (96.3% sensitivity). The study included 275,436 patients with COPD-heart failure overlap, with a mean follow-up period of 9.32 years. The COPD-heart failure overlap cohort had more medical service use and higher mortality than did the COPD alone cohort. Use of inhaled corticosteroid (ICS)/long-acting β2 agonist (LABA) combinations, long-acting muscarinic antagonist (LAMA), angiotensin receptor blockers (ARBs), β blockers, aldosterone antagonists, and statins reduced mortality risk compared with non-use. Sensitivity and subgroup analyses confirmed the consistency and robustness of results. ICS/LABA combinations, LAMA, ARBs, β blockers, aldosterone antagonists, and statins use was associated with a lower mortality risk in patients with COPD-heart failure overlap.
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) and heart failure (HF) are major global health issues characterized by high mortality and morbidity [1, 2] . The COPD-heart failure overlap leads to important therapeutic challenges. The cornerstones of COPD therapy are long-acting inhaled bronchodilators (anticholinergics and β2 agonists) with or without inhaled corticosteroids (ICSs) [1] . Improvements in medical treatment have shifted the treatment of HF from the use of positive inotropic agents to efforts to limit and slow its progression [2] . Angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β blockers, and aldosterone antagonists reduce hospitalization and mortality in patients with HF.
Although β blockers are established therapy for HF, this class of drugs is often underused in patients with COPD-HF overlap [3] . Furthermore, patients receiving ARBs were less likely to have cough compared with those receiving ACEIs [4] . ACEIrelated cough could lead to bronchial hyperresponsiveness [5] . Moreover, the presence of bronchial hyperresponsiveness in COPD is associated with increased mortality [6] . More evidence of the survival benefit of this therapy is needed. Therefore, the aim of this study was to investigate the survival effects of medications recommended in guidelines for patients with COPD-heart failure overlap using a populationbased nationwide dataset.
RESULTS

Clinical characteristics of the study population
After the application of exclusion criteria, the study cohort consisted of 611,618 patients with COPD alone and 275,436 patients with COPD-heart failure overlap ( Figure 1 ). The mean follow-up periods for the COPDheart failure overlap and COPD alone cohorts were 9.32 and 9.81 years, respectively. Table 1 shows the baseline characteristics of the cohorts. The percentage of COPDheart failure overlap patients increased significantly with age at the time of COPD diagnosis; the greatest proportion of these patients was aged ≥80 years (total, 45.90%; male, 40.56%; female, 53.66%; Figure 2A -2C). Compared with the COPD alone cohort, the COPD-heart failure overlap cohort was older (mean age, 64.38 vs. 70.63 years; p < 0.0001) and contained fewer men (64.02% vs. 59.14%; p < 0.0001). Compared with the COPD alone cohort, the COPD-heart failure overlap cohort had more outpatient visits (mean, 2.44 vs. 2.79), hospitalizations for COPD or HF (mean, 0.15 vs. 0.46; all p < 0.0001) per year.
Risk factors for mortality in patients with COPDheart failure overlap
The cumulative survival hazard was significantly lower in the COPD-heart failure overlap cohort than in the COPD alone cohort in Kaplan-Meier analysis (log-rank test, p < 0.001; Figure 3A ). Survival decreased significantly with increasing exacerbation frequency of COPD or HF in Kaplan-Meier analysis ( Figure 3B and 3C); this result was sustained after adjustment for other factors (Supplementary Table 1 ). We identified the following independent risk factors for mortality in the COPD-heart failure overlap cohort: age ≥ 65 years (HR, 1.59; 95% CI, 1.59-1.60), male sex (HR, 1.11; 95% CI, 
The effect of COPD medication use on mortality
In the time-dependent Cox proportional-hazards model, the use of LAMA, and ICS/LABA combinations was associated with significantly lower mortality risks AGING 0.77-0.78; all p < 0.0001; Table 2 ). In contrast, use of ICSs alone was associated with significantly higher mortality risks. The results of subgroup analyses are presented in Figure 4A -4E.
AGING
The effect of HF medication use on mortality
Among HF medication, the use of ARBs, cardioselective β blockers, non-selective β blockers, aldosterone antagonists, and statins was associated with significantly lower mortality risks (model 1 Table  2 ). However, digoxins use was associated with the highest mortality risk. The results of subgroup analyses are presented in Figure 4F -4M.
Validation of COPD and HF definitions
2,325 patients with COPD and 3,402 patients with HF were identified from the claims database of Taipei Veterans General Hospital. Then, 300 patients from each group were randomly selected for validation of diagnoses. Of them, 276 patients with COPD underwent pulmonary function test and 288 patients with HF underwent echocardiogram. Diagnoses of COPD were confirmed by pulmonologists in 282/300 subjects (94.0% sensitivity) and by pulmonary function test in 238/276 subjects (86.2% sensitivity). Diagnoses of HF were confirmed by cardiologists in 289/300 subjects (96.3% sensitivity) and by echocardiography in 263/288 subjects (91.3% sensitivity). 
DISCUSSION
This study revealed a greater medical burden in patients with COPD-heart failure overlap than in those with COPD alone. Our study demonstrated significant reductions in mortality associated with the use of LAMA, ICS/LABA combinations, ARBs, β blockers, aldosterone antagonists, and statins in patients with COPD-heart failure overlap. Results of this study, which involved large COPD-heart failure overlap and COPD cohorts -to our knowledge, the largest COPDheart failure overlap cohort examined to date -are more valuable than those of clinical trials because they more closely reflect real-world practice. Furthermore, the definitions of COPD and HF were validated in this study, which indicated that the accuracy was excellent.
AGING
Despite the Heart Failure Society of America's recommendation of β blocker use for HF [2] , we previously documented the suboptimal use of β blockers in patients with COPD-heart failure overlap due to concern about their detrimental effects on COPD [7] . A population-based survey conducted by Lipworth et al. in UK enrolled 24,237 patients with HF alone and 10,853 patients with COPD-heart failure overlap, and showed that the use of β blockers in combination with ACEI/ARB was much lower in patients with COPDheart failure overlap than in patients with HF alone (22.3% vs. 41.3%, p < 0.001) [3] . In turn, despite the Global Initiative for Chronic Obstructive Lung Disease's recommendation of bronchodilator use in patients with COPD and COPD-heart failure overlap [1] , concern about detrimental effects on HF has led to suboptimal use of these drugs [8] .
This study demonstrated that LAMA, ICS/LABA combinations, ARBs, β blockers, aldosterone antagonists, and statins reduced mortality in patients with COPD-heart failure overlap. We also showed that cardioselective β blockers (bisoprolol and metoprolol) yield better survival outcomes than do non-selective β blockers in patients with COPD-heart failure overlap. Pulmonary effects appear to differ among β blockers; non-selective, but not cardioselective, β blockers have been found to reduce forced expiratory volume in 1 second (FEV1) and to increase airway hypersensitiveness in patients with COPD [9] . In a randomized cross-over study [10] , bisoprolol is better tolerated than carvedilol on lung function in patients with moderate to severe COPD.
Paradoxically, as evidence for the efficacy of β blockers in COPD accumulates, studies have shown adverse cardiovascular effects of β agonists. The cardiac safety of LABA treatment, reported in clinical trials, is a result of administration by inhalation, which limits the transition of active drugs into the systemic circulation. However, inhaled β agonists still reach the systemic circulation through pulmonary circulation or absorption via the gastrointestinal tract after the swallowing of residual particles [11] . β agonists are associated with increased mortality and HF-related hospitalization in patients with existing HF [12] . A meta-analysis of randomized placebocontrolled trials showed that β-agonist treatment significantly increased the risk of a cardiovascular event in patients with obstructive airway disease compared with placebo (relative risk [RR] = 2.54; 95% CI, 1.59-4.05) AGING [13] . Not surprisingly, SABDs and LABAs alone use was associated with increased risk of mortality in this study. Tiotropium, an inhaled LAMA approved for COPD maintenance treatment that was examined in this study, was associated with lower mortality than placebo in clinical trial [14] . In clinical trial [15] , use of ICS/LABA combination over three years showed a decrease in mortality that almost reached statistical significance (HR=0.825, p = 0.052). A meta-analysis of randomized controlled trials showed that ICS/LABA combinations use was associated with a lower risk of death compared with use of ICSs alone [16] . According to international guideline for COPD [1] , ICS monotherapy is not recommended for the management of COPD. Among older patients with COPD, ICS/LABA combinations use was associated with a lower risk of death compared with use of LABAs alone [17] . Sensitivity and subgroup analyses demonstrated that the benefits of LAMA and ICS/LABA combinations in patients with COPD and HF were consistent.
The most common side effect of ACEI therapy is cough, the prevalence of which approaches 50% in Chinese populations [18] . The incidence of ACEI-related cough has been reported to be 2.7 folds higher in Chinese subjects compared with Caucasians [19] . ACEI-induced cough may represent bronchial hyperresponsiveness in some patients [5] . ARBs do not appear to induce cough or bronchial hyperreactivity in patients with symptomatic asthma [20] . Indeed, bronchial hyperresponsiveness is an independent predictor of mortality in COPD patients [6] . In this study, almost all enrollees were Taiwanese. Our study showed that ARBs use is associated with better survival outcomes than ACEIs use. Similarly, use of statins (RR = 0.53; 95% CI, 0.43-0.65) and ARBs (RR = 0.62; 95% CI, 0.44-0.87), but not ACEIs (RR = 1.04; 95% CI, 0.86-1.25), was associated with survival benefit in 22,784 patients with COPD and high cardiovascular risk in a time-matched nested case-control study [21] . In a double-blind, placebo-controlled, randomized controlled trial [22] , 80 patients with at least moderate COPD were randomized to either 10 weeks of therapy with an ACEI (10 mg enalapril) or placebo. Use of the ACEI significantly reduced the peak power response to exercise training in COPD patients. Recently, a population-based cohort study [23] also showed that statins use was associated with a lower mortality risk in patients with COPD.
In this study, use of SABDs, loop diuretics, and digoxins increased mortality risk in patients with COPD-heart failure overlap. Possible explanations for the higher mortality risk associated with SABD use are related to various cardiac side effects. In addition, excess SABD, loop diuretic, and digoxin use has been associated with poor control of COPD and HF, which may itself be the cause of this increased risk. Regardless of whether the association demonstrated is causal, however, chronic use of these drugs is a very powerful marker of high mortality risk in patients with COPD-heart failure overlap. Such patients warrant special attention. This study was strengthened by using a nationwide population-based data to conduct a real-world study, which enrolled nearly all cases of COPD and HF in Taiwan with minimal selection and referral biases, as the NHI coverage rate is >99% and all cardiopulmonary-related healthcare is covered. To minimize immortal time bias, medication use was analyzed using time-dependent covariates in the Cox proportionalhazards model. Nevertheless, this study has some limitations. First, the claim-based dataset omitted some personal information, such as data on smoking and obesity. Although these factors appear to have no influence on medication selection and we made every effort to correct for confounding factors. Second, we could not assess drug adherence directly. However, this bias is toward the null hypothesis and would lead to underestimation of the actual effects of medications. Finally, the external validity of the results of this study should be of concern because all enrollees were Taiwanese. The generalizability of our findings to nonAsian populations must be further verified.
METHODS
Data source
This cohort study used the Taiwan National Health Insurance Research Database (NHIRD), which is derived from the claims data of the Taiwan's National Health Insurance (NHI) program, initiated in 1995, from more than 99% of Taiwan's 23 million residents [24] . The NHIRD, provided for research purposes by Taiwan's National Health Research Institute, contains healthcare data from NHI participants, including information on demographic characteristics; medical diagnoses, procedure, expenditure, and all detailed prescriptions. The accuracy of diagnoses recorded in the NHIRD, such as sleep apnea [24] , pneumonia [24] , asthma [25] , COPD [25] , tuberculosis contact [26] , and tuberculosis [27] has been validated in our previous work. The study was exempted from full review by the Institutional Review Board of Taipei City Hospital because the datasets consisted of de-identified secondary data.
Study design and population
In this nationwide cohort study, we retrospectively analyzed medication effects on mortality in patients with COPD-heart failure overlap. All patients with COPD diagnoses recorded in the NHIRD between 1 AGING January 1997 and 31 December 2012 were divided into the COPD alone and COPD-heart failure overlap cohorts. COPD and HF were identified using diagnostic codes from the International Classification of Diseases, Information on the use of medications recommended in guidelines for patients with COPD or HF were extracted [1, 28] . Patients with follow-up periods < 1 year, those aged < 40 years, and those who were not prescribed medications for COPD or HF were excluded.
Potential confounders and severity classification
In the investigation of the effects of medications on mortality, age, sex, urbanization level, income level, Charlson Comorbidity Index, exacerbation frequency of COPD, exacerbation frequency of HF, and comorbidities were considered to be potential confounders. Because the most important factor in classifying COPD severity appears to be a previous history of exacerbations [29] , exacerbation frequency of COPD was determined using the annual frequency of hospitalizations and emergency department visits for acute exacerbation during the follow-up period. Exacerbation frequency of HF was classified in the same way and the negative correlation between COPD/HF severity and cumulative survival has been validated in our previous study [7] . Based on the number of acute exacerbations (AE) per year, patients were assigned to the 0 AE/year, >0 and <1 AE/year, ≥1 and <2 AE/year, ≥2 and <3 AE/year, and ≥3 AE/year groups.
Exposure to COPD and HF medications
Patients who took ≥28 days of each medication recommended in guidelines for patients with COPD or HF during the follow-up period, were assigned to respective medication groups. Prescriptions of medications for COPD or HF were assessed during each time period (3 months or 1 year) for each individual patient [30] . A 3-month period was chosen, because medications are usually prescribed for 3 months at a time. A 1-year period was used to recheck the robustness of the results of 3-month period. COPD medication groups were: shortacting bronchodilators (SABDs), including short-acting β2 agonists (albuterol, fenoterol, terbutaline, procaterol) and short-acting muscarinic antagonists (ipratropium); long-acting β2 agonists (LABAs; salmeterol, formoterol, bambuterol, indacaterol); long-acting muscarinic antagonist (LAMA; tiotropium); ICSs (budesonide, fluticasone, beclomethasone) and ICS/LABA combinations (fluticasone/salmeterol, budesonide/ formoterol, beclomethasone/formoterol). HF medication groups were: ACEIs (benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, perindopril, quinapril, ramipril), ARBs (losartan, candesartan, valsartan, irbesartan, telmisartan, eprosartan, olmesartan, azilsartan), cardioselective β blockers (bisoprolol, metoprolol), nonselective β blockers (carvedilol), loop diuretics (furosemide, bumetanide), aldosterone antagonists (spironolactone, eplerenone); digoxins (digoxin, digitoxin), and statins (atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin).
Validation
The claims database of Taipei Veterans General Hospital (a 3,035-bed tertiary referral hospital in Taiwan) was used to validate the accuracy of the diagnoses of COPD and HF in this study. The contents of this database are used for reimbursement and are similar to those of the NHIRD [24] [25] [26] [27] . The diagnoses of COPD and HF were validated by analysis of selected samples from this database using the same criteria. COPD was defined as COPD diagnosed by a pulmonologist, or fixed airflow limitation determined by pulmonary function test [1] . HF was defined as HF diagnosed by a cardiologist, or inadequate cardiac output determined by echocardiography [2] . Random sampling of claims data for validation was performed using SPSS version 20.
Statistical analyses
Data entry and analysis were performed using SAS statistical software (version 9.4; SAS Institute, Cary, NC, USA). Descriptive analysis was used to compare the COPD alone group and COPD-heart failure overlap group in terms of demographic data and the prescription medications during the study period. All the data were presented as mean ± standard deviation (SD) or percentage (%). Comparison between two groups was made by independent Student's t-test for continuous variables or Pearson's chi-square test for categorical variables as appropriate. Kaplan-Meier survival analysis and the log-rank test were used to examine the difference between the cohorts. We used the Cox proportional-hazards regression models to determine the survival effect of medication use during the follow-up period. Medication prescriptions in each 3-month and 1-year period served as time-dependent covariates. Patients who were prescribed ≥28 days of each medication within each interval were assigned to the respective medication groups and all others were defined as non-users [25] . Other baseline variables were AGING analyzed as non-time-dependent covariates. All factors with p values < 0.1 in univariate analyses were included in the Cox multivariate analysis. The hazard ratio (HR) and 95% confidence intervals (CIs) were calculated after adjustment for possible confounding factors. Twotailed p values < 0.05 were considered statistically significant. Subgroup analyses were performed according to age, sex, exacerbation frequency of COPD and HF.
CONCLUSIONS
This study demonstrated that patients with COPD-heart failure overlap have more outpatient visits per year, more hospitalization, and a shorter time to mortality than do patients with COPD alone. LAMA, ICS/LABA combination, ARB, β blocker, aldosterone antagonist, and statin use decreased the mortality risk. 
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